0
0
10/17/22 at 4:02pm
Organization
Targetedonc.com
Author
Ariana Pelosci
39 words
0
Comments
At the NCCN Annual Congress:Hematologic Malignancies, David J. Straus, MD debated if this was the best course of action for treating Hodgkin lymphoma.
You are the first to view
https://www.targetedonc.com/view/brentuximab-vedotin-shows-promising-activity-as-first-line-use-in-classical-hodgkin-lymphoma
Create an account
or login to join the discussion